Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 27Myeloid 6Sarcoma 1Gastrointestinal 1Classical hematology 1

Conditions

Leukemia, Myelomonocytic, Acute 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 11fludarabine phosphate 9Whole-Body Irradiation 8Mycophenolic Acid 7Busulfan 6fludarabine 5Tacrolimus 5Peripheral Blood Stem Cell Transplantation 5Melphalan 5Rituximab 4Biopsy 4Azacitidine 4venetoclax 3apixaban 3Cyclosporine 3thymoglobulin 2decitabine and cedazuridine drug combination 2Vorinostat 2Vancomycin 2Tretinoin 2Specimen Handling 2Sirolimus 2Methotrexate 2Lenalidomide 2Injections 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Etoposide 2Decitabine 2Cytarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Idarubicin × Classical hematology × 90 days × Clear all
NCT00801489 2026-03-30

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 2 Recruiting
270 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡